Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365396 | 0.91 | PDGFRB (0.76) | PDGFRBPDGFRAKDREGFRFGFR2 | |
| SCHEMBL168048 | 0.89 | PDGFRB (0.79) | PDGFRBPDGFRAKDREGFRFGFR2 | |
| SCHEMBL3894947 | 0.88 | PDGFRA (0.76) | PDGFRBPDGFRAKDREGFRFGFR2 | |
| SCHEMBL12486420 | 0.87 | PDGFRA (0.71) | PDGFRBPDGFRAKDREGFRFGFR2 | |
| SCHEMBL31669062 | 0.87 | PDGFRA (0.71) | PDGFRBPDGFRAKDREGFRFGFR2 | |
| Hydrochloric Acid SCHEMBL3906500 | 0.86 | PDGFRA (0.74) | PDGFRBPDGFRAKDREGFRFGFR2 | |
| SCHEMBL1893450 | 0.86 | KDR (0.68) | PDGFRBPDGFRAKDREGFRFGFR2 | |
| SCHEMBL4482576 | 0.86 | PDGFRA (0.69) | PDGFRBPDGFRAKDREGFRFGFR2 | |
| SCHEMBL30467929 | 0.86 | PDGFRA (0.69) | PDGFRBPDGFRAKDREGFRFGFR2 | |
| SCHEMBL29137432 | 0.86 | PDGFRA (0.69) | PDGFRBPDGFRAKDREGFRFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | claimed |
| EP-2262772-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-12-22 | — | — | EP | claimed |
| WO-2009127417-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-10-22 | — | — | WO | claimed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-8999982-B2 | Pharmaceutically active compounds as Axl inhibitors | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| EP-2609091-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2609091-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-21 | — | — | US | disclosed |
| EP-1652847-A1 | Quinoline and quinazoline derivatives for the treatment of tumors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1535910-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-6821987-B2 | 4-SUBSTITUTED BY AZOLYLUREIDO-PHENOXY, OR PHENYLTHIO; ANTITUMOR AGENTS; TREATING DIABETIC RETINOPATHY, CHRONIC RHEUMATISM, PSORIASIS, ATHEROSCLEROSIS, | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-23 | — | — | US | disclosed |
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-18 | — | — | US | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1382604-A1 | QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2003-05-08 | — | — | US | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | PDGFRB 2/4885PDGFRA 1/4885KDR 4/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | PDGFRB 2/4885PDGFRA 1/4885KDR 5/4885 |
| US-20140018365-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS | AXL, FLT3, ERBB3 | PDGFRB 56/4885PDGFRA 69/4885KDR 30/4885 |
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | NQO2, H1-5, NRAS | PDGFRB 4361/4885PDGFRA 4104/4885KDR 3455/4885 |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | NQO2, H1-5, NRAS | PDGFRB 4361/4885PDGFRA 4104/4885KDR 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.